Pharmaron Acquires Bridge China To Become Fully-integrated CRO
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Pharmaron, a Beijing-headquartered contact research organization, announced Jan. 11 that it has acquired Bridge Laboratories China, a leading preclinical CRO in China, to add toxicology services to its portfolio
You may also be interested in...
Going Deeper Into China: AstraZeneca Strikes Drug Discovery Partnership With CRO Pharmaron
AstraZeneca continues its investments in China, setting up a comprehensive discovery partnership with Chinese CRO Pharmaron, which acquired preclinical CRO Bridge in 2010.
Going Deeper Into China: AstraZeneca Strikes Drug Discovery Partnership With CRO Pharmaron
AstraZeneca continues its investments in China, setting up a comprehensive discovery partnership with Chinese CRO Pharmaron, which acquired preclinical CRO Bridge in 2010.
Merck Serono Opens Bioanalysis Center In Beijing To Support Clinical Trials In Asia; Plans To Double Staff
SHANGHAI - Merck KGaA's biopharmaceutical arm Merck Serono SA opened Aug. 31 a new R&D laboratory in Beijing to establish bioanalysis capability that will support clinical trials in Asia. The site is on Chinese contract research organization Pharmaron's new campus in the Beijing Economic and Technological Development Area